CD274 and hepatocellular carcinoma: Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer death in the US and the fourth worldwide.1 Treatment of advanced HCC has been revolutionized with the introduction of immunotherapy regimens targeting the PD-1/PD-L1 axis, yet only a subset of patients respond to such therapies.